window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : May 1, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

clinical development

  • Cell & Gene Therapy,Clinical Development,Regulatory Affairs

    Nanoscope Therapeutics begins FDA submission for gene-agnostic therapy to treat retinitis pigmentosa

    Nanoscope Therapeutics has initiated a rolling submission for its Biologics [...]

    July 15, 2025
  • Uncategorised

    Pharvaris eyes 2026 filing as Phase 3 HAE trial timeline shifts

    Pharvaris has adjusted its guidance for topline results from its [...]

    July 10, 2025
  • Clinical Development,Market Access & Commercialization,Oncology,Partnerships & Funding

    VIVES Partners joins Nuclidium AG’s €84M Series B Financing to advance copper-based radiopharmaceuticals

    VIVES Partners, managing company of VIVES Funds, has joined a [...]

    July 10, 2025
  • Clinical Development,Clinical Trials,Patient Centricity

    Phesi CEO warns of looming Phase 3 trial failures as sponsors overlook real-world data and overcrowd sites

    New analysis reveals billions risked on overly complex trials that [...]

    July 10, 2025
  • Artificial Intelligence,Drug Development

    Ochre Bio founder takes helm as CEO to drive RNA liver therapies towards clinic

    RNA therapeutics biotech Ochre Bio has appointed its founder and [...]

    July 7, 2025
  • Artificial Intelligence,Clinical Development,Drug Development,Market Access & Commercialization,Partnerships & Funding,Patient Centricity

    Lisata and GATC expand partnership to develop AI-discovered treatment for opioid use disorder

    New alliance targets early 2026 for first-in-human trial of non-opioid [...]

    July 1, 2025
  • CDMOs & Manufacturing,Cell & Gene Therapy,Drug Development,Oncology,Partnerships & Funding,Technology and platforms

    Mabion manufactures first batch of NovalGen’s bispecific T-cell engager for clinical trials

    Poland-based CDMO Mabion has completed the first GMP-compliant batch of [...]

    June 27, 2025
  • Artificial Intelligence,Clinical Trials,Technology and platforms

    RBQMLive returns in 2025 with agenda on regulation, ROI and AI in clinical trials

    CluePoints releases full speaker lineup for free virtual event focused [...]

    June 23, 2025
  • Artificial Intelligence,Clinical Trials

    PhaseV raises $50M to expand AI-powered clinical trial platform

    PhaseV has secured $50 million in Series A funding to [...]

    May 13, 2025
  • Market Access & Commercialization,Partnerships & Funding

    Alchemab Therapeutics signs $415m licensing deal with Lilly for ALS program

    May 6, 2025
Previous456Next

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Currax highlights peer-reviewed review supporting combination approaches in obesity treatment
    Categories: Obesity, Pharmaceuticals and therapeutics, Research & Development
  • MaaT Pharma publishes real-world CHRONOS data in third-line acute GvHD
    Categories: Clinical Development, Clinical studies, Hematology, Regulatory Affairs, Research & Development
  • Symbiosis expands QC capabilities with new 30°C stability chamber
    Categories: CDMOs & Manufacturing, Facilities and infrastructure, Manufacturing, Pharmaceuticals and therapeutics
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top